During recent decades, the emergence of pathogenic fungi has posed an increasing public
health threat, particularly given the limited number of antifungal drugs available to treat …

Fungal infections are a major contributor to infectious disease-related deaths across the
globe. Candida species are among the most common causes of invasive mycotic disease …

Candida albicans and the emerging non-albicans Candida spp. have significant clinical
relevance among many patient populations. Current treatment guidelines include …

Within the limited antifungal armamentarium, the azole antifungals are the most frequent
class used to treat Candida infections. Azole antifungals such as fluconazole are often …

The epidemiology of Candida infections has changed in recent years. Although Candida
albicans is still the main cause of invasive candidiasis in most clinical settings, a substantial …

Fungal infections, such as candidiasis caused by Candida, pose a problem of growing
medical concern. In developed countries, the incidence of Candida infections is increasing …

The increased use of antibacterial and antifungal agents in recent years has resulted in the
development of resistance to these drugs. The significant clinical implication of resistance …

Metal nanoparticles used as antifungals have increased the occurrence of fungal–metal
interactions. However, there is a lack of knowledge about how these interactions cause …

Invasive fungal infections are increasingly common in the nosocomial setting. Furthermore,
because risk factors for these infections continue to increase in frequency, it is likely that …

Fungi cause serious infections in the immunocompromised and debilitated, and the
incidence of invasive mycoses has increased significantly over the last 3 decades. Slow …